PTAB Institutes Trial on a “Follow-On” IPR Petition Following Two Previous Denials

Mar 6, 2018

Reading Time : 2 min

The PTAB has the discretion under § 314(a) to deny institution of an IPR for multiple follow-on petitions.  The PTAB detailed seven factors in General Plastic Indus. Co. Ltd. v. Canon Kabushiki Kaisha, IPR2016-01357, Paper No. 19 (PTAB Sept. 6, 2017) (precedential) that it looks to “when determining whether to exercise that discretion.”  The PTAB has previously exercised its discretion to deny so-called “follow-on petitions” that stage arguments in multiple petitions to use petitioner’s preliminary responses as a “roadmap” to gain institution.  The General Plastic factors that the PTAB weighs are non-exhaustive and principally include:

  • whether the same petitioner previously sought review of the same patent claims;
  • whether, at the time of the first petition filing, the petitioner knew about the prior art listed in the second petition; and
  • whether, at the time of the second petition filing, the petitioner had received the patent owner’s preliminary response from the first petition.

The Patent Owner argued that Petitioners had not met the General Plastic factors because their petition challenged the same patent claims, Petitioners knew of the prior art references, and Petitioners had already received the Patent Owner’s preliminary response.  Nonetheless, the PTAB declined to exercise its discretion to deny institution of the IPR.

The PTAB’s decision to not exercise its discretion turned on Petitioners’ belated discovery that the Patent Owner had endorsed two prior art methods for practicing a claim element in a parallel European Patent Office proceeding.  Upon discovering this potentially invalidating art, Petitioners immediately hired experts to conduct testing.  Petitioners then filed the third IPR petition only eight days after they completed testing.  The PTAB determined that Petitioners’ efforts to investigate and complete testing on a matter not at issue in the two initial petitions was reasonable. Petitioners’ diligent actions stood in stark contrast to the disallowed practice from General Plastic wherein a petitioner “strategically stage[d] [its] prior art and arguments in multiple petitions, using [Patent Owner’s preliminary response] as a roadmap, until a ground is found that results in the grant of review.” IPR2016-01357, slip op. at 17.

Relatedly, the PTAB has discretion to decline IPR institution under 35 U.S.C. § 325(d) if “the same or substantially the same prior art or arguments previously were presented to the [Patent] Office.”  The PTAB considered this threshold issue in this proceeding, and its analysis tracked the above § 314(a) reasoning.  The PTAB determined that, because the patent examiner did not have Petitioners’ new testing evidence, the Patent Office had not considered the same prior art.

Ultimately, Petitioners demonstrated a reasonable likelihood that they would prevail on both of the unpatentability grounds.  This case suggests that the PTAB may allow “follow-on” petitions in some cases if a Petitioner is diligent in filing the petition and has a reasonable basis for not raising the grounds in an earlier Petition..

Sanofi-Aventis U.S. LLC v. Immunex Corp., IPR2017-01884, Paper No. 14 (PTAB Feb. 15, 2018)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.